Panelist discusses how the second interim overall survival data from MARIPOSA-2, presented at the European Society for ...

The congress is a collaboration of the European Society for Medical Oncology (ESMO), the European SocieTy for Radiotherapy ...

Company Achieves Milestones in Both Clinical ProgramsInitiates Mipletamig Phase 1b/2 Clinical Trial, "RAINIER," in Frontline Acute Myeloid Leukemia, Informed by Positive Dose Escalation Trial ...

Goldman Sachs has upgraded BioNTech SE (NASDAQ:BNTX), citing the company’s BNT327, an immuno-oncology asset in clinical ...

Evidence suggests that combining metformin with standard of care could increase survival and offer other benefits to patients with high-volume disease.

Investigators report findings from a phase 3 trial demonstrating that transdermal estradiol patches were as effective as luteinizing hormone-releasing hormone agonists.

HONG KONG, SHANGHAI, and FLORHAM PARK, N.J., Nov. 05, 2024 (GLOBE NEWSWIRE) -- (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from the sovleplenib ESLIM-01 Phase III ...

CureVac (CVAC) announced that new and updated data will be shared in two oral presentations and four posters at the 12th International mRNA ...

Issuer: CureVac / Key word (s): Conference CureVac to Present at the 12th International mRNA Health Conference 04.11.2024 / 13:00 CET/CEST The issuer is solely responsible for the content of this ...

J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...

Michael Platten is the winner of the “Breakthrough of the Year 2024” in the Life Sciences category of the Falling Walls Foundation.

Additionally, positive findings from trials like ADRIATIC (NCT03703297) and IMforte (NCT05091567) are further shaping ...